Merck KGaA's Stimuvax Misses Primary Endpoint In Phase III Trial-DJ

Dow Jones reported that Merck KGaA said a Phase III trial of Stimuvax on patients with non small cell lung cancer didn't meet the primary endpoint, or a significant improvement in overall survival. Stimuvax refers to Merck's product L-BLP25. Despite not meeting the primary endpoint, notable treatment effects were seen for L-BLP25 in certain subgroups. Further analysis is planned in the coming weeks to explore the potential benefit-risk profile of L-BLP25 in certain populations. Merck KGaA has an exclusive licensing agreement with U.S.-based Oncothyreon Inc. (ONTY) for Stimuvax.